COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY
Geert R. D'Haens 1
Julian Panés 2
Edouard Louis 3
Qian Zhou 4
John Liu 4
Ana P. Lacerda 4
Edward V. Loftus 5
1 AMC Amsterdam Inflammatory Bowel Disease Centre, Amsterdam, Netherlands
2 Hospital Clinic Barcelona, Barcelona, Spain
3 University Hospital of Liège, Liège, Belgium
4 Abbvie, North Chicago, United States
5 Mayo Clinic, Rochester, United States
Topic
IBD, Immunology
Session
IBD: Clinical trials I
Conference
UEG Week Virtual 2020
Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]